Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 119941
Published online Jun 27, 2026. doi: 10.4240/wjgs.119941
Published online Jun 27, 2026. doi: 10.4240/wjgs.119941
Anti-reflux mucosectomy is associated with better short-term symptoms than double-dose proton pump inhibitor in reflux esophagitis patients
Wen-Jun Jiang, Jie Liu, Ying-Ling Liu, Meng-Die Tang, Yuan Sheng, Ye-Tao Wang, Department of Gastroenterology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui Province, China
Co-first authors: Wen-Jun Jiang and Jie Liu.
Author contributions: Jiang WJ and Liu J drafted the original manuscript; Liu YL conducted and Tang MD conducted the gastroscopy; Sheng Y and Wang YT supervised the study and made critical revisions; Wang YT conceptualized, designed, supervised the study and made critical revisions; Jiang WJ and Liu J contributed equally for the study completion and manuscript writing, they were listed as co-first authors; all authors prepared the final draft and approved the final version.
Supported by the Scientific Research Plan Project of Universities in Anhui Province, No. 2024AH052045.
Institutional review board statement: This study received approval from the Ethics Committee of Anhui Provincial Hospital, No. XJS2022-2-18(NK).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-a checklist of items.
Data sharing statement: Data, analytic methods, and study materials are available to other researchers upon request to the corresponding author.
Corresponding author: Ye-Tao Wang, MD, Chief Physician, Department of Gastroenterology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. wangyt96@163.com
Received: February 11, 2026
Revised: March 11, 2026
Accepted: April 3, 2026
Published online: June 27, 2026
Processing time: 131 Days and 7.2 Hours
Revised: March 11, 2026
Accepted: April 3, 2026
Published online: June 27, 2026
Processing time: 131 Days and 7.2 Hours
Core Tip
Core Tip: Anti-reflux mucosectomy (ARMS) is an innovative endoscopic technique developed for the management of refractory gastroesophageal reflux disease. The procedure aims to induce submucosal fibrosis following mucosectomy at the esophagogastric junction, offering the advantage of a minimally invasive endoscopic approach. Since its inception, multiple prospective and retrospective studies have been conducted to evaluate the clinical outcomes associated with ARMS. In this context, we present the findings of a retrospective cohort study comparing the efficacy of ARMS to twice-daily proton pump inhibitor (PPI) therapy in a well-defined population of patients exhibiting moderate-to-severe regurgitation despite once-daily PPI treatment.